Gilead Sciences, Inc. (GILD) Quick Ratio (Acid-Test): 1.31
Is Gilead Sciences, Inc.’s quick ratio (acid-test) high or low?
Gilead Sciences, Inc.'s quick ratio (acid-test) of 1.31 is in line with its 5-year average of 1.26, around the middle of its 5-year range (1.13–1.45).
As of Thursday, June 11, 2026. 5.07% below its 12-month average of 1.38.
GILD Quick Ratio (Acid-Test) Chart
GILD Average Quick Ratio (Acid-Test) Chart
GILD Current vs Average Quick Ratio (Acid-Test) Chart
GILD Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
1.31
QUICK RATIO (ACID-TEST) AVG TTM
1.38
QUICK RATIO (ACID-TEST) AVG 3Y
1.29
QUICK RATIO (ACID-TEST) AVG 5Y
1.26
QUICK RATIO (ACID-TEST) AVG 10Y
1.89
QUICK RATIO (ACID-TEST) AVG 15Y
2.02
QUICK RATIO (ACID-TEST) AVG 20Y
2.33
CURRENT VS TTM AVG
-5.07%
CURRENT VS 3Y AVG
+1.16%
CURRENT VS 5Y AVG
+3.83%
CURRENT VS 10Y AVG
-30.75%
CURRENT VS 15Y AVG
-35.15%
CURRENT VS 20Y AVG
-43.85%
GILD Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | $156.35B | 1.31 | 1.38 | 1.29 | 1.26 |
| Abbott Laboratories (ABT) | $155.75B | 1.18 | 1.21 | 1.20 | 1.26 |
| Pfizer Inc. (PFE) | $149.61B | 0.87 | 0.90 | 0.87 | 0.95 |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 3.96 | 3.59 | 3.74 | 4.30 |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 1.53 | 1.41 | 1.34 | 1.37 |
| CVS Health Corporation (CVS) | $126.70B | 0.63 | 0.61 | 0.63 | 0.63 |
| Danaher Corporation (DHR) | $126.39B | 1.51 | 1.28 | 1.37 | 1.36 |
| Amgen Inc. (AMGN) | $188.37B | 0.90 | 0.93 | 1.02 | 1.14 |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 1.14 | 1.15 | 1.19 | 1.27 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.59B | 2.46 | 2.41 | 3.31 | 3.62 |
Liquidity Comparison
Quick Ratio
1.31
Excludes inventory
Current Ratio
1.68
Includes inventory
Gilead Sciences, Inc. Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gilead Sciences, Inc. Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for Gilead Sciences, Inc. (GILD)?
- The quick ratio (acid-test) for GILD stock is 1.31.
- Is Gilead Sciences, Inc.'s quick ratio (acid-test) high or low?
- Gilead Sciences, Inc.'s quick ratio (acid-test) of 1.31 is in line with its 5-year average of 1.26, around the middle of its 5-year range (1.13–1.45).
- What is the TTM average quick ratio (acid-test) for Gilead Sciences, Inc. (GILD)?
- The TTM average quick ratio (acid-test) for GILD stock is 1.38.
- What is the 3Y average quick ratio (acid-test) for Gilead Sciences, Inc. (GILD)?
- The 3Y average quick ratio (acid-test) for GILD stock is 1.29.
- What is the 5Y average quick ratio (acid-test) for Gilead Sciences, Inc. (GILD)?
- The 5Y average quick ratio (acid-test) for GILD stock is 1.26.
- What is the 10Y average quick ratio (acid-test) for Gilead Sciences, Inc. (GILD)?
- The 10Y average quick ratio (acid-test) for GILD stock is 1.89.
- What is the 15Y average quick ratio (acid-test) for Gilead Sciences, Inc. (GILD)?
- The 15Y average quick ratio (acid-test) for GILD stock is 2.02.
- What is the 20Y average quick ratio (acid-test) for Gilead Sciences, Inc. (GILD)?
- The 20Y average quick ratio (acid-test) for GILD stock is 2.33.
Gilead Sciences, Inc. Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 1.31 |
| 2024-12-31 | 1.45 |
| 2023-12-31 | 1.27 |
| 2022-12-31 | 1.15 |
| 2021-12-31 | 1.13 |
| 2020-12-31 | 1.26 |
| 2019-12-31 | 3.01 |
| 2018-12-31 | 3.30 |
| 2017-12-31 | 2.67 |
| 2016-12-31 | 1.95 |
| 2015-12-31 | 2.31 |
| 2014-12-31 | 2.83 |
| 2013-12-31 | 0.83 |
| 2012-12-31 | 1.04 |
| 2011-12-31 | 4.98 |
| 2010-12-31 | 1.83 |
| 2009-12-31 | 2.01 |
| 2008-12-31 | 2.74 |
| 2007-12-31 | 3.30 |
| 2006-12-31 | 2.44 |
| 2005-12-31 | 6.18 |
| 2004-12-31 | 6.76 |
| 2003-12-31 | 6.28 |
| 2002-12-31 | 10.79 |
| 2001-12-31 | 8.34 |
| 2000-12-31 | 9.84 |
| 1999-12-31 | 7.33 |
| 1998-12-31 | 6.99 |
| 1997-12-31 | 10.19 |
| 1996-12-31 | 18.65 |
Related Metrics
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day